{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:46:11Z","timestamp":1768315571888,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-03370-4","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T06:50:50Z","timestamp":1748155850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["P-gp quantification for cell resistance studies in leukemia cells using the innovative LightSpot-FL-1 fluorescent conjugate"],"prefix":"10.1038","volume":"15","author":[{"given":"Maxime","family":"Dubois","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Goisnard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Bourgne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elodie","family":"Gay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Depresle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"Roux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Voisin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Penault-Llorca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Mounetou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Daumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahchid","family":"Bamdad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,25]]},"reference":[{"key":"3370_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0304-419X(96)00022-4","volume":"1288","author":"I Bosch","year":"1996","unstructured":"Bosch, I. & Croop, J. P-glycoprotein multidrug resistance and cancer. Biochim. Biophys. Acta BBA Rev. Cancer 1288, 37\u201354 (1996).","journal-title":"Biochim. Biophys. Acta BBA Rev. Cancer"},{"key":"3370_CR2","doi-asserted-by":"publisher","first-page":"59950","DOI":"10.18632\/oncotarget.19048","volume":"8","author":"H-C Zheng","year":"2017","unstructured":"Zheng, H.-C. The molecular mechanisms of chemoresistance in cancers. Oncotarget 8, 59950\u201359964 (2017).","journal-title":"Oncotarget"},{"key":"3370_CR3","doi-asserted-by":"publisher","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","volume":"95","author":"LA Doyle","year":"1998","unstructured":"Doyle, L. A. et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. 95, 15665\u201315670 (1998).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"3370_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0304-3835(00)00646-7","volume":"162","author":"E Hopper","year":"2001","unstructured":"Hopper, E. et al. Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Lett. 162, 181\u2013191 (2001).","journal-title":"Cancer Lett."},{"key":"3370_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/0-306-46812-3_13","volume":"12","author":"JA Silverman","year":"1999","unstructured":"Silverman, J. A. Multidrug-resistance transporters. Pharm. Biotechnol. 12, 353\u2013386 (1999).","journal-title":"Pharm. Biotechnol."},{"key":"3370_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/jnci\/81.2.116","volume":"81","author":"LJ Goldstein","year":"1989","unstructured":"Goldstein, L. J. et al. Expression of multidrug resistance gene in human cancers. JNCI J. Natl. Cancer Inst. 81, 116\u2013124 (1989).","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"3370_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1128\/MMBR.00001-07","volume":"71","author":"J Lubelski","year":"2007","unstructured":"Lubelski, J., Konings, W. N. & Driessen, A. J. M. Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria. Microbiol. Mol. Biol. Rev. MMBR 71, 463\u2013476 (2007).","journal-title":"Microbiol. Mol. Biol. Rev. MMBR"},{"key":"3370_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","volume":"455","author":"RL Juliano","year":"1976","unstructured":"Juliano, R. L. & Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta BBA - Biomembr. 455, 152\u2013162 (1976).","journal-title":"Biochim. Biophys. Acta BBA - Biomembr."},{"key":"3370_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0145-2126(00)00156-9","volume":"25","author":"P Ferrao","year":"2001","unstructured":"Ferrao, P., Sincock, P., Cole, S. & Ashman, L. Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia. Leuk. Res. 25, 395\u2013405 (2001).","journal-title":"Leuk. Res."},{"key":"3370_CR10","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.3390\/cancers13164050","volume":"13","author":"A Goisnard","year":"2021","unstructured":"Goisnard, A. et al. LightSpot\u00ae-FL-1 fluorescent probe: An innovative tool for cancer drug resistance analysis by direct detection and quantification of the P-glycoprotein (P-gp) on monolayer culture and spheroid triple negative breast cancer models. Cancers 13, 4050 (2021).","journal-title":"Cancers"},{"key":"3370_CR11","doi-asserted-by":"publisher","first-page":"27016","DOI":"10.1039\/D3RA05093A","volume":"13","author":"P Daumar","year":"2023","unstructured":"Daumar, P. et al. Chemical biology fluorescent tools for in vitro investigation of the multidrug resistant P-glycoprotein (P-gp) expression in tumor cells. RSC Adv. 13, 27016\u201327035 (2023).","journal-title":"RSC Adv."},{"key":"3370_CR12","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.2147\/OTT.S191621","volume":"12","author":"J Zhang","year":"2019","unstructured":"Zhang, J., Gu, Y. & Chen, B. Mechanisms of drug resistance in acute myeloid leukemia. OncoTargets Ther. 12, 1937\u20131945 (2019).","journal-title":"OncoTargets Ther."},{"key":"3370_CR13","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345\u20131377 (2022).","journal-title":"Blood"},{"key":"3370_CR14","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1182\/blood-2023-179325","volume":"142","author":"H Liu","year":"2023","unstructured":"Liu, H. et al. 1- and 5-year survival for adults with acute myeloid leukaemia and 30-day mortality after initial systemic anti-cancer therapy, with an exploration of factors associated with poorer outcomes: Data from a national registry in England, 2013\u20132020. Blood 142, 2846 (2023).","journal-title":"Blood"},{"key":"3370_CR15","first-page":"711","volume":"85","author":"C Wuchter","year":"2000","unstructured":"Wuchter, C. et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 85, 711\u2013721 (2000).","journal-title":"Haematologica"},{"key":"3370_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/10428190500032612","volume":"46","author":"DP Olson","year":"2005","unstructured":"Olson, D. P. et al. The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: A retrospective study of 295 newly diagnosed patients by the Children\u2019s Oncology Group. Leuk. Lymphoma 46, 681\u2013691 (2005).","journal-title":"Leuk. Lymphoma"},{"key":"3370_CR17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/pbc.21707","volume":"51","author":"M van Grotel","year":"2008","unstructured":"van Grotel, M. et al. CD34 expression is associated with poor survival in pediatric T-cell acute lymphoblastic leukemia. Pediatr. Blood Cancer 51, 737\u2013740 (2008).","journal-title":"Pediatr. Blood Cancer"},{"key":"3370_CR18","first-page":"204","volume":"14","author":"AI Svirnovski","year":"2009","unstructured":"Svirnovski, A. I. et al. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. Hematol. Amst. Neth. 14, 204\u2013212 (2009).","journal-title":"Hematol. Amst. Neth."},{"key":"3370_CR19","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645\u2013648 (1994).","journal-title":"Nature"},{"key":"3370_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/cyto.b.20403","volume":"74","author":"LL de Figueiredo-Pontes","year":"2008","unstructured":"de Figueiredo-Pontes, L. L. et al. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. Cytometry B Clin. Cytom. 74, 163\u2013168 (2008).","journal-title":"Cytometry B Clin. Cytom."},{"key":"3370_CR21","doi-asserted-by":"publisher","first-page":"7599","DOI":"10.1158\/1078-0432.CCR-04-0598","volume":"10","author":"L Su\u00e1rez","year":"2004","unstructured":"Su\u00e1rez, L. et al. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes. Clin. Cancer Res Off. J. Am. Assoc. Cancer Res. 10, 7599\u20137606 (2004).","journal-title":"Clin. Cancer Res Off. J. Am. Assoc. Cancer Res."},{"key":"3370_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1006\/abbi.2000.2004","volume":"383","author":"E Wang","year":"2000","unstructured":"Wang, E., Casciano, C. N., Clement, R. P. & Johnson, W. W. Cooperativity in the Inhibition of P-glycoprotein-mediated daunorubicin transport: Evidence for half-of-the-sites reactivity. Arch. Biochem. Biophys. 383, 91\u201398 (2000).","journal-title":"Arch. Biochem. Biophys."},{"key":"3370_CR23","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/(SICI)1097-0215(19960516)66:4<520::AID-IJC16>3.0.CO;2-B","volume":"66","author":"BW Futscher","year":"1996","unstructured":"Futscher, B. W. et al. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int. J. Cancer 66, 520\u2013525 (1996).","journal-title":"Int. J. Cancer"},{"key":"3370_CR24","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0022-3565(25)12089-2","volume":"275","author":"EG Schuetz","year":"1995","unstructured":"Schuetz, E. G., Furuya, K. N. & Schuetz, J. D. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J. Pharmacol. Exp. Ther. 275, 1011\u20131018 (1995).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"3370_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1124\/dmd.113.053819","volume":"42","author":"B Prasad","year":"2014","unstructured":"Prasad, B. et al. Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: Quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab. Dispos. 42, 78\u201388 (2014).","journal-title":"Drug Metab. Dispos."},{"key":"3370_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00280-023-04578-9","volume":"92","author":"JF Marcelletti","year":"2023","unstructured":"Marcelletti, J. F. & Sikic, B. I. A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): Evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype. Cancer Chemother. Pharmacol. 92, 369\u2013380 (2023).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"3370_CR27","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00280-024-04656-6","volume":"93","author":"JF Marcelletti","year":"2024","unstructured":"Marcelletti, J. F. & Sikic, B. I. Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype. Cancer Chemother. Pharmacol. 93, 595\u2013604 (2024).","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03370-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03370-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03370-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T06:50:51Z","timestamp":1748155851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03370-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,25]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3370"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-03370-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,25]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Our study exclusively involves patient-derived cells without any associated clinical data. According to the ethical regulations of our institution and French law (Article L.1211-2 al.2 du Code de la sant\u00e9 publique), such research does not require Institutional Review Board (IRB) approval. Additionally, as per our institutional policy, all patients systematically sign a non-opposition statement, allowing the use of their biological samples for research purposes. Indeed, all patients included in the study were informed via the CHU Clermont-Fd welcome booklet that the remaining biological samples taken during their diagnosis and follow-up could be used for research unless they objected; no patient expressed their objection. All methods were carried out in accordance with relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"18173"}}